The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19

The PIKfyve inhibitor apilimod is currently undergoing clinical trials for treatment of COVID-19. However, although apilimod might prevent viral invasion by inhibiting host cell proteases, the same proteases are critical for antigen presentation leading to T cell activation and there is good evidenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Baranov, Maksim V., Bianchi, Frans, van den Bogaart, Geert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824419/
https://www.ncbi.nlm.nih.gov/pubmed/33375410
http://dx.doi.org/10.3390/cells10010030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824419/
https://www.ncbi.nlm.nih.gov/pubmed/33375410
http://dx.doi.org/10.3390/cells10010030

Ejemplares similares